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Introduction: Dual antiplatelet therapy (DAPT) represents one of the pillars in the treatment of acute 
coronary syndromes (ACS)1. In the past the most commonly used combination of antiplatelet drugs 
has been acetylsalicylic acid (ASA) and clopidogrel. Clopidogrel had a high incidence rate of high re-
sidual platelet reactivity and has, in recent years, been replaced with ticagrelor, a more potent platelet 
inhibitor with a more uniformed response across the patient population. The effect of high dose ator-
vastatin on platelet reactivity mediated by ASA and clopidogrel is well researched, however no studies 
have been published analyzing this effect when clopidogrel is 
substituted with ticagrelor. Purpose: To investigate if high dose 
atorvastatin modifies PF mediated by DAPT in patient with 
ACS as measured by platelet function tests (PFTs). 
Patients and Methods: We analyzed clinical characteristics 
and PF in patients presenting with ACS at the Department of 
Cardiovascular Diseases at the University Hospital Centre Za-
greb from December 2015 to February 2018. Primary endpoint 
was PF after treatment with DAPT and/or high dose atorvas-
tatin. We analyzed PF using the Multiplate platelet function 
analyzer. PFTs were performed 18-24 hours after therapy ini-
tiation. None of the patients were taking statins before the in-
dex event. 
Results: There were 35 patients with a mean (SD) age of 61.6 
(12.2) years in the atorvastatin group and 29 patients with a 
mean (SD) of 62.6 (9.6) years in the no-atorvastatin group. Both 
groups were identical in all the baseline parameters except 
history of hyperlipidemia (34.5% vs 65.7%, P=0.023). There were 
no significant differences between the two groups in PF ana-
lyzed with PFTs (Figure 1). The difference in residual platelet 
reactivity remained non-significant even after adjusting for 
sex, age and hyperlipidemia as the only co-variate that was 
significantly different between the group (P=0.432). 
Conclusion: In this pilot study on a limited sample we found no difference in residual PF in patients 
on DAPT weather they are on treatment with high dose atorvastatin or not. These results show that 
the pleiotropic effects of atorvastatin on platelet reactivity are not significant in patients taking DAPT 
with ticagrelor and ASA. 
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Figure 1. platelet reactivity with and without high dose atorvastatin.
NS = non-significant.
